This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

IQIRVO® (elafibranor) therapeutic indication1

IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.1

PBC Today

PBC Today

Many patients remain at risk of disease progression despite treatment2–4

Potential risk factors

Factors like race, age, disease severity, and presence of symptoms can increase risk of disease progression5–12

Potential risk factors

Non-response of treatment

ALP is not adequately controlled in up to 40% of patients treated with UDCA*2–4

Non-response of treatment

Second-line treatments are needed to manage PBC progression and lessen symptom impact13

To date, second-line treatments:

May have incomplete effects, with limitations in managing the underlying cholestasis and inflammation of PBC12,14,15

May worsen PBC symptoms, such as pruritus, to the point of causing treatment discontinuation12,14